- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02507661
Effect of Alveolar Ridge Preservation on Implant Esthetic Outcomes
March 21, 2018 updated by: Bozidar Brkovic, DDS, MSc, PhD, Professor, University of Belgrade
Esthetic Outcomes of Implant-supported Crowns After Alveolar Ridge Preservation With Beta Tricalcium Phosphate and Collagen in the Maxillary Esthetic Zone
The purpose of this study is to evaluate esthetic outcome of implant supported single crowns after alveolar ridge preservation with beta three calcium phosphate with collagen type I in aesthetic region in upper jaw.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
- Drug: preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months
- Drug: no-preservation of alveolar ridge - 2 months
- Drug: preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months
- Drug: no-preservation of alveolar ridge - 4 months
- Procedure: preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months
- Drug: no-preservation of alveolar ridge - 9 months
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Belgrade, Serbia, 11000
- School of dental medicine, University of Belgrade
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- healthy patients according to Classification of American Society of Anesthesiologists (ASA I)
- presence of 4 socket walls
- non-smokers
- good oral hygiene
- good occlusion
Exclusion Criteria:
- patients with alveolar ridge height less than 12 mm
- presence of acute or chronic oro-facial pain
- acute periapical infection
- injured soft tissue
- patients who had dental interventions in last 7 days
- patients who had any medications within last 24 hours
- patients with bruxism and para-functions
- patients with allergies to any of applied materials
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: alveolar ridge preservation - 2 months
preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months
|
|
ACTIVE_COMPARATOR: no-preservation of alveolar ridge - 2 months
|
|
EXPERIMENTAL: preservation of alveolar ridge - 4 months
preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months
|
|
ACTIVE_COMPARATOR: no-preservation of alveolar ridge - 4 months
|
|
EXPERIMENTAL: preservation of alveolar ridge - 9 months
preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months
|
|
ACTIVE_COMPARATOR: no-preservation of alveolar ridge - 9 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
implant stability analysis at the time of implant placement
Time Frame: baseline
|
Implant stability will be measured by the resonance frequency analysis
|
baseline
|
implant stability analysis 3 weeks after implant placement
Time Frame: baseline, 3 weeks
|
Implant stability will be measured by the resonance frequency analysis
|
baseline, 3 weeks
|
implant stability analysis 6 weeks after implant placement
Time Frame: baseline, 6 weeks
|
Implant stability will be measured by the resonance frequency analysis
|
baseline, 6 weeks
|
implant stability analysis 8 weeks after implant placement
Time Frame: baseline, 8 weeks
|
Implant stability will be measured by the resonance frequency analysis
|
baseline, 8 weeks
|
change in pink and white esthetic score 2 months of loading
Time Frame: 2 months
|
Pink esthetic scale and white esthetic scale will be used for evaluation of changes in white and pink esthetic parameters for implant-supported crowns
|
2 months
|
change in pink and white esthetic score 6 months of loading
Time Frame: 6 months
|
Pink esthetic scale and white esthetic scale will be used for evaluation of changes in white and pink esthetic parameters for implant-supported crowns
|
6 months
|
change in pink and white esthetic score 12 months of loading
Time Frame: 12 months
|
Pink esthetic scale and white esthetic scale will be used for evaluation of changes in white and pink esthetic parameters for implant-supported crowns
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
analysis of new bone formation 2 months after preservation of alveolar ridge
Time Frame: 2 months
|
New bone formation will be assessed by histological analysis and histomorphometrical measurement
|
2 months
|
analysis of new bone formation 4 months after preservation of alveolar ridge
Time Frame: 4 months
|
New bone formation will be assessed by histological analysis and histomorphometrical measurement
|
4 months
|
analysis of new bone formation 9 months after preservation of alveolar ridge
Time Frame: 9 months
|
New bone formation will be assessed by histological analysis and histomorphometrical measurement
|
9 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Bozidar M Brkovic, PhD, School of dental medicine, University of Belgrade
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 1, 2015
Primary Completion (ACTUAL)
January 1, 2018
Study Completion (ACTUAL)
January 1, 2018
Study Registration Dates
First Submitted
June 11, 2015
First Submitted That Met QC Criteria
July 23, 2015
First Posted (ESTIMATE)
July 24, 2015
Study Record Updates
Last Update Posted (ACTUAL)
March 23, 2018
Last Update Submitted That Met QC Criteria
March 21, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- 36/21
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Partial Edentulism
-
Nobel BiocareCompletedPartial Edentulism | Complete Edentulism
-
Nobel BiocareCompletedPartial Edentulism | Complete Edentulism
-
Semmelweis UniversityInstitut Straumann AG; Geistlich Pharma AG; Dicomlab Kft.Recruiting
-
Fundación Eduardo AnituaActive, not recruitingPartial-edentulismSpain
-
Fundación Eduardo AnituaActive, not recruitingPartial-edentulismSpain
-
University of Colorado, DenverCompletedPartial EdentulismUnited States
-
University of BaghdadUnknown
-
Navigate Surgical Technologies Inc.CompletedPartial EdentulismCanada
-
Institut Straumann AGCompletedPartial EdentulismUnited States, Austria, Germany, Ireland, Netherlands, Portugal, Spain, Sweden, Switzerland
-
Institut Straumann AGCompletedPartial Edentulism
Clinical Trials on preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months
-
Second Affiliated Hospital, School of Medicine,...RecruitingAlveolar Bone ResorptionChina
-
International Piezosurgery AcademyCompleted
-
Fundación Eduardo AnituaRecruiting
-
Tanta UniversityCompletedChronic Periodontitis | Intrabony Periodontal Defect | Concentrated Growth FactorsEgypt
-
Stanford UniversityWithdrawn
-
Ocular Therapeutix, Inc.Completed
-
University of New MexicoAmerican College of Clinical PharmacyCompleted
-
Jonsson Comprehensive Cancer CenterParker Institute for Cancer ImmunotherapyRecruitingRecurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | CD20 Positive | Refractory Mantle Cell Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Refractory... and other conditionsUnited States
-
The Cleveland ClinicUniversity of NottinghamRecruitingMultiple Sclerosis, Relapsing-RemittingUnited States, United Kingdom
-
University of NebraskaNational Cancer Institute (NCI)CompletedRecurrent Mantle Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Negative | Recurrent Anaplastic Large Cell LymphomaUnited States